Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.225
-0.015 (-1.21%)
Sep 28, 2026, 1:26 PM EDT - Market open
Cardiff Oncology Employees
As of December 31, 2025, Cardiff Oncology had 31 total employees, including 30 full-time and 1 part-time employees. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$16,387
Profits / Employee
-$1,292,774
Market Cap
95.30M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 31 | -2 | -6.06% | 30 | 1 |
| Dec 31, 2024 | 33 | 1 | 3.13% | 32 | 1 |
| Dec 31, 2023 | 32 | 6 | 23.08% | 31 | 1 |
| Dec 31, 2022 | 26 | 3 | 13.04% | 25 | 1 |
| Dec 31, 2021 | 23 | 11 | 91.67% | 22 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Adicet Bio | 102 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| PMV Pharmaceuticals | 54 |
| Biomea Fusion | 37 |
| NeurAxis | 24 |
| Tenax Therapeutics | 16 |
CRDF News
- 13 days ago - Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright - TheFly
- 14 days ago - Cardiff Oncology Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 14 days ago - Cardiff Oncology, Nerviano Medical Sciences reach settlement - TheFly
- 14 days ago - Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement - GlobeNewsWire
- 26 days ago - Cardiff Oncology to Participate in September 2026 Conferences - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology Proxy statement: Proxy filing - Filings
- 4 weeks ago - Cardiff Oncology Proxy statement: Proxy filing - Filings
- 6 weeks ago - Cardiff Oncology reports Q2 EPS (14c), consensus (16c) - TheFly